13. The pharmaceutical composition in accordance with any preceding claim, formulated for mammalian administration, and preferably, for human administration.

14. The pharmaceutical composition in accordance with any preceding claim, adapted and configured as part of a therapeutic kit that comprises the composition, and at least a first set of instructions for administration of the composition to a human in need thereof.

15. The pharmaceutical composition in accordance with any preceding claim, for use in therapy, prophylaxis, or amelioration of one or more symptoms of a mammalian cancer.

16. The pharmaceutical composition in accordance with any preceding claim, for use in the therapy, prophylaxis, or amelioration of one or more symptoms of a human breast cancer, and in particular, a human therapy-resistant, metastatic, or triple-negative breast cancer.

17. A pharmaceutical composition in accordance with any one of claims 1 to 16, for use in therapy.

18. A pharmaceutical composition in accordance with any one of claims 1 to 16, for use in the treatment of cancer in a mammalian subject.

19. Use of a pharmaceutical composition in accordance with any one of claims 1 to 13, in the manufacture of a medicament for treating or ameliorating one or more symptoms of cancer in a mammal.

20. Use in accordance with claim 19, in the manufacture of a medicament for treating human breast cancer, and in particular, a refractory, a treatment-resistant, a relapsed, a metastatic, or a triple-negative breast cancer.

21. Use of a pharmaceutical composition in accordance with any one of claims 1 to 16, in the manufacture of a medicament for treating or ameliorating one or more symptoms of cancer in a mammal.

22. The use in accordance with claim 21, wherein the cancer is diagnosed as, or is identified as, a refractory, a metastatic, a relapsed, or a treatment-resistant cancer.

23. The use in accordance with claim 21 or claim 22, wherein the cancer is diagnosed as, or is identified as, a treatment-resistant or a metastatic cancer, and in particular, a treatment-resistant, triple-negative human breast cancer.

24. The use in accordance with any one of claims 21 to 23, wherein a therapeutically-effective amount of radiation is to be further administered to the animal.

25. The use in accordance with any one of claims 19 to 24, wherein the pharmaceutical composition is to be administered systemically to the animal, in a single administration, or in a series of multiple administrations over a period of from one or more days, over a period of one or more weeks, or over a period of one or more months or longer.

26. The use in accordance with any one of claims 19 to 25, wherein the pharmaceutical composition further comprises a second distinct chemotherapeutic agent, or a second distinct iNOS inhibitor in accordance with any one of claims 1 to 16.